Actively Recruiting

Phase Not Applicable
Age: 18Years - 90Years
All Genders
NCT05963191

CAD-EYE System for the Detection of Neoplastic Lesions in Patients With Lynch Syndrome

Led by PERROD Guillaume · Updated on 2025-09-03

272

Participants Needed

1

Research Sites

104 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Lynch syndrome (LS) is the most common genetic predisposition syndrome for colorectal cancer (CRC), responsible for around 2-4% of cancers. It is characterized by a pathogenic germline mutation in one of the DNA mismatch repair genes (path\_MMR) MLH1, MSH2, MSH6, PMS2 or a deletion in the 3' region of the Epcam gene. Patients followed up for LS are at high risk of developing CRC at an early age, and have a high cumulative CRC risk. In this context, CRC screening by colonoscopy is of major importance, as it is associated with a reduction in both CRC incidence and mortality. In France, the Institut National du Cancer (INCa) recommends colonoscopy with indigo carmine chromoendoscopy (CE), as it is associated with a significant increase in the adenoma detection rate (ADR) compared with white light. However, EC is not routinely performed in clinical practice, as it is a time-consuming technique requiring a dedicated slot with a trained operator. Recent years have seen the emergence of artificial intelligence techniques for real-time polyp detection aids or CADe devices. These easy-to-use systems have shown very promising results compared with high-definition (HD) white light. Indeed, data from the first meta-analysis of 5 randomized controlled trials (4354 patients) confirmed a significantly higher ADD in the CADe group than in the HD group (36.6% vs. 25.2%; 95% CI\], 1.27-1.62; P \< 0.01; I2 Z 42%) 10. The CAD EYE system (Fujifilm) is a CADe device supporting both detection (sensitivity \> 95%) and characterization of colonic polyps in real time. To date, artificial intelligence has never been evaluated for CRC screening in patients followed up for LS. The aim of this work is to evaluate the effectiveness of the CAD EYE system in this specific population. To this end, we intend to conduct a randomized, controlled, non-inferiority trial comparing CAD EYE with CE in patients with LS.

CONDITIONS

Official Title

CAD-EYE System for the Detection of Neoplastic Lesions in Patients With Lynch Syndrome

Who Can Participate

Age: 18Years - 90Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Confirmed pathogenic mutation in one of the Lynch syndrome genes (MLH1, MSH2, MSH6, PMS2, or EpCAM)
  • Male or female of legal age at time of colonoscopy prescription
  • Patient agrees to participate in the study
  • Person affiliated with or benefiting from a social security scheme
  • Free, informed, and express consent provided
Not Eligible

You will not qualify if you...

  • Patient has undergone total colectomy with ileoanal or ileosigmoid anastomosis
  • History of Crohn's disease or ulcerative colitis
  • Known allergy or intolerance to polyethylene glycol and ascorbic acid
  • Unable to undergo fractionated colonic preparation
  • Inadequate colonic preparation with Boston sub-score less than 2 per segment
  • Patient is under guardianship or a protected person
  • Patient does not understand French or cannot read
  • Person not affiliated to a social security system
  • Pregnant women

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Hôpital Européen Georges-Pompidou HEGP

Paris, France, 75015

Actively Recruiting

Loading map...

Research Team

G

Guillaume Perrod, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

DIAGNOSTIC

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here